ClinicalTrials.gg
RecruitingNCT06234501Updated Oct 7, 2026

Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism

An interventional study of Pyridoxal 5'-Phosphate (100 mg) and Placebo in Autism, sponsored by University of Reading. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Reading · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 7, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Autistic Disorder with a site in United Kingdom — 10 open to participants now, 14 under way, none of them phase 3. Autistic Disorder · United Kingdom.

Planned enrollment
14th of 21
40 · median 69
Started
2024
with 5 others
No phase
19 of 37
6 open now
Primary completion
2026-11
later than 10 of 13 live
Registered
26th of 37
by date

Among the 37 studies in Autistic Disorder with a site in United Kingdom, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2024, is one of 19 with no phase, reaches primary completion later than 10 of the 13 other live ones, and was the 26th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

10 of the 37 studies in Autistic Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Autistic Disorder with a site in United Kingdom, or all of them as a file.
02

Study summary

This clinical trial aims to explore the effect of Vitamin B6 supplementation on anxiety sensory hyperreactivity in autistic adults. Researchers will compare a placebo group to high-dose Vitamin-B6 to see if vitamin B6 reduce anxiety and sensory reactivity differences in autism.

Read the detailed description

The main question it aims to answer is:

  • Does high-dose Vitamin B6 supplementation reduce sensory hyperreactivity differences in autism?
  • Does high-dose Vitamin B6 supplementation reduce anxiety differences in autism?
  • Explore the effects of vitamin B6 on sleep quality, Attention Deficit Hyperactivity Disorder (ADHD) scores, and various visual perception tasks that are indicative of GABAergic activity
03

Conditions studied

  • Autism

Browse trials for

Keywords

  • Vitamin B6
  • Sensory Hyperreactivity
  • GABA
  • Excitation-Inhibition Balance
  • Autism
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18 to 60
  • With a diagnosis of autism

Exclusion criteria

Exclusion Criteria:

  • Taking any supplement that contains more than 2mg of Vitamin B6 or taking GABA agonist drugs
  • Have a medical history of peripheral neuropathy
  • lactose intolerance (placebo tablet is lactose based)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Vitamin-B6

    Participants will consume one high-dose Vitamin B6 100 mg tablet orally once daily for one month. Vitamin B6 will be provided as Pyridoxal-5'-Phosphate (PLP)

    Dietary Supplement: Pyridoxal 5'-Phosphate (100 mg)

  • Placebo comparator
    Placebo

    Participants will consume a Placebo tablet matching the appearance of the Vitamin B6 tablets in the Experimental arm orally once daily for one month.

    Other: Placebo

Interventions

  • Dietary supplementPyridoxal PhosphateStudies of Pyridoxal PhosphatePyridoxal Phosphate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 mg Pyridoxal 5'-Phosphate tablet once daily with food

    Also known as: Vitamin B6

  • OtherPlacebo

    Placebo tablet once daily

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. Sensory hyperreactivity

    Sensory hyperreactivity will be measured by a subscale of the Sensory Processing Inventory (SP3D.

    Time frame: Baseline and One month

  2. Sensory hyperreactivity

    Sensory hyperreactivity will be measured by a subscale of the Comprehensive Autistic Trait Inventory (CATI).

    Time frame: Baseline and One month

  3. Anxiety

    Anxiety will be measured using the Screen for Adult Anxiety Related Disorders (SCAARED) questionnaire.

    Time frame: Baseline and One month

  4. Vitamin B6 status

    The concentration of different forms of Vitamin B6 in blood plasma will be measured (Pyridoxal-5'-phosphate, pyridoxine, pyridoxal, pyridoxamine)

    Time frame: Baseline and One month

Secondary outcomes

  1. ADHD traits

    Adult Attention Deficit Hyperreactivity Disorder Self-Report Scale (ASRS-v1.1)

    Time frame: Baseline and One month

  2. Sensory processing differences

    These will be measured using the other subscales of the Sensory Processing Inventory (SP3D) that do not constitute the primary sensory hyperreactivity outcome described above.

    Time frame: Baseline and One month

  3. Sleep quality

    Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Baseline and One month

  4. Visual Surround Suppression of contrast perception

    Psychophysical measurements of the contrast threshold will be made, which correspond to the minimum physical stimulus contrast that can be reliably detected by an observer. The test measures the increase in the threshold caused by introducing spatial inhibition of the target stimuli, which is a parameter that has been shown to correlate with GABA concentration in the brain (Yoon et al., 2010).

    Time frame: Baseline and One month

  5. Surround Suppression of Motion duration detection thresholds

    Psychophysical measurements of the motion duration threshold will be made, which correspond to the number of milliseconds an observer requires to detect whether a Gabor patch is drifting left or right. The test measures the increase in the threshold caused by spatial inhibition, which is a parameter that has been shown to differ in various patient groups, including autism (Foss-Feig et al. 2013).

    Time frame: Baseline and One month

  6. Binocular Rivalry reversal rate

    A test based on presenting ambiguous visual stimuli that cause perceptual reversals; how frequently the perceptual reversals occur is measured and has been shown to be related to GABA levels (Mentch et al., 2019).

    Time frame: Baseline and One month

  7. Binocular Rivalry suppression index

    A test based on presenting ambiguous visual stimuli that cause perceptual reversals; the proportion of time for which the stimulus appears unclear rather than stable is measured and has been shown to be related to GABA levels (Mentch et al., 2019).

    Time frame: Baseline and One month

  8. Measurement of Weber Fraction for size perception

    The Weber fraction is the percentage change in a physical quantity required for an observer to reliably detect that a change has occurred, and for a specific stimulus type it is generally a fixed percentage regardless of the magnitude of the stimuli. We will measure the Weber Fraction for visual size perception at four separate starting sizes, and the outcome measure derived from doing that will be a measurement of the stability/instability of the Weber Fraction across the four starting sizes. It has been reported that in autism the general finding of fixed Weber fractions across a range of physical stimuli does not hold (Hadad \& Schwartz, 2019): we are taking the opportunity to replicate this finding.

    Time frame: Baseline and One month

  9. Tilt illusion magnitude

    Magnitude of the tilt illusion is a correlate of GABA concentration in the occipital cortex (Song et al., 2017).

    Time frame: Baseline and One month

  10. Ebbinghaus illusion magnitude

    Magnitude of the Ebbinghaus illusion is a correlate of gamma y-Aminobutyric acid (GABA) concentration in the parietal lobe (Song et al. 2017)

    Time frame: Baseline and One month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, Ragland JD, Carter CS. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci. 2010 Mar 10;30(10):3777-81. doi: 10.1523/JNEUROSCI.6158-09.2010. PubMed 20220012 ↗
  • Mentch J, Spiegel A, Ricciardi C, Robertson CE. GABAergic Inhibition Gates Perceptual Awareness During Binocular Rivalry. J Neurosci. 2019 Oct 16;39(42):8398-8407. doi: 10.1523/JNEUROSCI.0836-19.2019. Epub 2019 Aug 26. PubMed 31451579 ↗
  • Song C, Sandberg K, Andersen LM, Blicher JU, Rees G. Human Occipital and Parietal GABA Selectively Influence Visual Perception of Orientation and Size. J Neurosci. 2017 Sep 13;37(37):8929-8937. doi: 10.1523/JNEUROSCI.3945-16.2017. Epub 2017 Aug 14. PubMed 28821653 ↗
  • Hadad BS, Schwartz S. Perception in autism does not adhere to Weber's law. Elife. 2019 Mar 4;8:e42223. doi: 10.7554/eLife.42223. PubMed 30829198 ↗
  • Foss-Feig JH, Tadin D, Schauder KB, Cascio CJ. A substantial and unexpected enhancement of motion perception in autism. J Neurosci. 2013 May 8;33(19):8243-9. doi: 10.1523/JNEUROSCI.1608-12.2013. PubMed 23658163 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 24 months is close to that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jul 2026 → Nov 2026 and completion Jul 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Jan 31, 2024
StartActual
Nov 8, 2024
Primary completionEst.
Nov 13, 2026was Jul 2026
CompletionEst.
Nov 13, 2026was Jul 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Nov 13, 2026
Oct 7, 2026
Study completion
Jul 2026→Nov 13, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Jul 2026→Nov 13, 2026
    Study completion Jul 2026→Nov 13, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06234501
Collaborators
INNOPURE
Responsible party
David Field (Associate professor, University of Reading) — Principal investigator
First posted
Jan 31, 2024
Start date
Nov 8, 2024
Primary completion
Nov 13, 2026 (estimated)
Completion
Nov 13, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Dr David T Field, PhD
Contact
d.t.field@reading.ac.uk
+441183785004
Alex Cameron, MSc
Contact
a.cameron@pgr.reading.ac.uk
Dr David T Field, PhD
principal investigator · University of Reading

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyridoxal Phosphate

Start the discussion